Virttu
is engaged in the discovery and development of oncolytic immunotherapy for the treatment of cancer... Read moreVirttu
is engaged in the discovery and development of oncolytic immunotherapy for the treatment of cancer... Read more
CEO
Add
News
Apr 28, 2017
BioSpace
Virttu: Sorrento Announces Closing Of Its Acquisition Of Virttu Biologics
Apr 27, 2017
San Diego Business Journal
Virttu: TNK Therapeutics Inc. to Acquire Scotland-Based Co. in $34.4M Deal
Nov 20, 2016
BioPortfolio
Virttu: TNK Therapeutics to acquire Glasgow based biopharma company Virttu Biologics
Jan 05, 2016
BioSpace
VIRTTU: Virttu Biologics To Present At 2016 In San Francisco
Nov 09, 2015
BIOSPACE
VIRTTU: Data Demonstrating That SEPREHVIR (Virttu Biologics) Combines Synergistically With Anti-PD-1 Immune Checkpoint Inhibitor To Be Presented At AACR's Advances In Pediatric Cancer Research.
Nov 09, 2015
PR NEWSWIRE
Press Release: VIRTTU : Data Demonstrating That SEPREHVIR® (VIRTTU Biologics) Combines Synergistically With Anti-PD-1 Immune Checkpoint Inhibitor To Be Presented At AACR's Advances In Pediatric Cancer Research.
Nov 05, 2015
BIOSPACE
VIRTTU: <b>Virttu Biologics</b> Shows Robust Evidence Of Immunological Activity In Mesothelioma Patients Following SEPREHVIR Administration Results To Be Presented At <b>Society For ImmunoTherapy Of Cancer (SITC)</b>
Oct 19, 2015
BIOSPACE
VIRTTU: Virttu Biologics Announces Appointment Of As Chief Executive Officer
Oct 19, 2015
PR NEWSWIRE
Press Release: VIRTTU : Virttu Biologics Announces Appointment Of Deirdre Y. Gillespie As Chief Executive Officer
Virttu Competitors
1
2
3
4
5
6
7
8
9
10